Fortis HealthcareQ3 FY24

Fortis Healthcare Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹806.8P/E: 56.8Market Cap: ₹60.9K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Fortis Healthcare plans to add approximately 2,200 beds over the next 4 years, focusing primarily on brownfield expansions within existing hospitals to leverage operational efficiencies.
  • New facility openings include a 70-bed unit in Ludhiana and bed additions in Mulund, Kolkata, Bangalore, and Manesar, supporting volume growth.
  • Revenue growth is expected from increased occupancy (currently around 64-67%, with a target to reach ~70% and beyond), and a rising contribution from high-end specialties like oncology, neurosciences, and robotic surgeries.
  • ARPOB (Average Revenue per Occupied Bed) growth will moderate from previous high levels (~19%) to a sustainable ~5% driven by a growing mix of complex, high-value procedures.
  • International patient revenue is stabilizing after recent geopolitical impacts and is expected to return to prior levels.
  • Digital channel revenues grew 32% YoY, indicating growth in digital engagement and revenues from online sources.

See what Fortis Healthcare management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The transcript provided on pages 4-16 of the document does not explicitly mention any current or planned new fundraising through debt or equity.
  • The balance sheet remains healthy with a net debt to EBITDA ratio of 0.45x as of Q3 FY24, indicating manageable leverage.
  • There is no mention of raising new capital through equity or additional debt in the near term.
  • The company is focusing on operational improvements, bed expansions, and divestments but no active fundraising exercises are disclosed.
  • Private equity investors in Agilus have an exit timeline around April 2024, connected to a potential IPO, but no direct new equity issuance by the company is detailed.
  • Overall, no explicit plans or announcements of fresh fundraising through debt or equity are described in the current transcript.

See what Fortis Healthcare management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company has already spent INR 450 crores in capex during the current 9 months, with similar trends expected in the coming quarter.
  • Investments include state-of-the-art technology such as Gamma Knife, MR-Linac, two Linac replacements, a Da Vinci robotic surgery system, and an orthopedic robot (~INR 5-6 crores).
  • The focus is on expanding high-end specialties like oncology, neurology, and robotic surgeries to drive ARPOB increases and margin improvements.
  • Brownfield bed expansions are planned to add nearly 2,200 beds over the next 4 years, with ~350 beds from an acquired hospital (Medeor, Manesar) and other expansions across existing facilities.
  • New facilities and expansions (e.g., Ludhiana, Manesar, Noida) will be operationalized based on occupancy ramp-up to ensure cost-effective bed addition.
  • Strategic moves include portfolio rationalization by divesting loss-making facilities to improve overall profitability.
  • The company maintains margin guidance aiming for 25% EBITDA margin over 3-4 years with these investments.

Track Fortis Healthcare — get its next earnings analysis in your feed

How does Fortis Healthcare rank vs peers in Healthcare Services?

Pro feature
ThisFortis Healthcare
Rev 3Mar 3

How does Fortis Healthcare rank in Healthcare Services?

Compare Fortis Healthcare against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →